Follow Us On
Tablet
Files
Raloxifene HCl
Strength: 60mg
Count: 50
NDC
50268-694-15
Class
Rx
Brand Name
Evista
Imprint Code
AN057
Color(s)
WHITE (off-white)
Shape
OVAL
Score
no score
Case Count
NA
Inactive Ingredients
Anhydrous lactose, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone, silicon dioxide and titanium dioxide.
Indications and Usage
1.Treatment and Prevention of Osteoporosis in Postmenopausal Women Raloxifene hydrochloride (HCl) tablets, USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women. 2. Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Raloxifene HCl tablets, USP are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.. 3. Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer Raloxifene HCl tablets, USP are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years. Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known. High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Healthcare professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-545-5979. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty. After an assessment of the risk of developing breast cancer, the decision regarding therapy with raloxifene HCl tablets, USP should be based upon an individual assessment of the benefits and risks. Raloxifene HCl tablets, USP does not eliminate the risk of breast cancer. Patients should have breast exams and mammograms before starting raloxifene HCl tablets, USP and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with raloxifene HCl tablets, USP. Important Limitations of Use for Breast Cancer Risk Reduction: •There are no data available regarding the effect of raloxifene HCl tablets, USP on invasive breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of raloxifene HCl tablets, USP. •Raloxifene HCl tablets, USP are not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence. •Raloxifene HCl tablets, USP are not indicated for the reduction in the risk of noninvasive breast cancer.
